ACOG — Alpha Cognition Inc. Common Stock
Alpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company offers ZUNVEYL (benzgalantamine) for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury. It also develops ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.
Company profile
- Sector: Financial Services
- Industry: Financial - Conglomerates
- Country: CA
- Exchange: NASDAQ
- Employees: 5
- Website: https://www.alphacognition.com
Latest SEC filings for ACOG
- SCHEDULE 13G — 2026-09-23
- SCHEDULE 13G/A — 2026-07-24
- SCHEDULE 13G/A — 2026-06-29
- 8-K — 2026-06-23
- 10-Q — 2026-05-14
- SCHEDULE 13G/A — 2026-05-12
- SCHEDULE 13G/A — 2026-05-11
- 8-K/A — 2026-05-01
- 8-K — 2026-04-20
- 8-K — 2026-04-14
Latest ACOG news
- — Alpha Teknova (TKNO) Stock Jumps 5.1%: Will It Continue to Soar? (Zacks Investment Research)
- — Alpha Cognition Announces Publication of U.S. Patent Application Relating to Proprietary Manufacturing Process for ZUNVEYL® (businesswire.com)
- — Reviewing Alpha Cognition (NASDAQ:ACOG) & Karyopharm Therapeutics (NASDAQ:KPTI) (defenseworld.net)
Educational tool only — not investment advice.